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Abstract
Cationic antimicrobial peptides are ancient and ubiquitous immune effectors that multicellular organisms use to kill and
police microbes whereas antibiotics are mostly employed by microorganisms. As antimicrobial peptides (AMPs) mostly
target the cell wall, a microbial ‘Achilles heel’, it has been proposed that bacterial resistance evolution is very unlikely and
hence AMPs are ancient ‘weapons’ of multicellular organisms. Here we provide a new hypothesis to explain the widespread
distribution of AMPs amongst multicellular organism. Studying five antimicrobial peptides from vertebrates and insects, we
show, using a classic Luria-Delbru¨ck fluctuation assay, that cationic antimicrobial peptides (AMPs) do not increase bacterial
mutation rates. Moreover, using rtPCR and disc diffusion assays we find that AMPs do not elicit SOS or rpoS bacterial stress
pathways. This is in contrast to the main classes of antibiotics that elevate mutagenesis via eliciting the SOS and rpoS
pathways. The notion of the ‘Achilles heel’ has been challenged by experimental selection for AMP-resistance, but our
findings offer a new perspective on the evolutionary success of AMPs. Employing AMPs seems advantageous for
multicellular organisms, as it does not fuel the adaptation of bacteria to their immune defenses. This has important
consequences for our understanding of host-microbe interactions, the evolution of innate immune defenses, and also sheds
new light on antimicrobial resistance evolution and the use of AMPs as drugs.
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Introduction
Ever since the advent of antibiotics, bacterial resistance has
evolved and spread very rapidly [1] and recently has been shown
to be ancient [2]. This led to the suggestion to use cationic
antimicrobial peptides (AMPs) as alternatives, as these have been
successfully used by multicellular organisms over millions of years
[3]. While isolates from patients and wild animals display cationic
antimicrobial peptide resistance [4,5], which can be readily
achieved in vitro [6], a fundamental observation still holds:
cationic antimicrobial peptides are core components of the
antimicrobial defences in animals [3], whereas synthesis and use
of antibiotics is common in micro-organisms [7].
Here we suggest an explanation for this dichotomy based on the
firmly established observation that antibiotics elicit stress-induced
mutagenesis, which has been proposed to be adaptive in stressful
environments as it increases evolvability [8,9]. When stress leads to
DNA damage, a common way of antibiotic action, the bacterial
SOS pathway is activated and the DNA is repaired using an error-
prone alternative polymerase [8]. The other main stress pathway
rpoS increases mutation rates in a similar fashion [10]. It has been
suggested that antibiotic treatment should be enhanced with
mutation inhibitors interfering with the SOS pathway to increase
the lifetime of antibiotics [11]. Antibiotics mostly interfere with
replication, transcription and protein synthesis, in contrast cationic
antimicrobial peptides of multicellular organisms mostly target the
cell wall [12]. As such there is little potential of eliciting the SOS or
rpoS stress pathways and to elevate bacterial mutation rates, a
notion that we test here. This addresses the novel hypothesis that
the use of antimicrobial peptides in multicellular organisms as a
main effector against pathogens has been selected for because of
the differences in mutagenesis between AMPs and antibiotics.
To investigate our hypothesis we selected a panel of AMPs and
three conventional antibiotics as controls. We selected different
cationic antimicrobial peptides such as Cecropin A and Melittin
(both from insects) and magainin II and its derivative Pexiganan,
LL-37 and a human lysozyme from vertebrates to represent
different branches of the metazoa. For Mellitin, Magainin,
Pexiganan and LL-37 the proposed killing mechanism is toroidal
pore forming, while cecropin is considered to form a carpet on the
bacterical cell wall [13]. As controls, we use Kanamycin (targets
protein synthesis), Ampicillin (targets cell wall synthesis) and
Ciprofloxacin (blocks topoisomerases) to represent the most
important families of bactericidal antibiotics (Aminoglycosides,
Beta-Lactam, Fluoroquinolone).
Results
Mutation rates of E. coli treated with antimicrobial
peptides and antibiotics
We first investigated the mutation rates of E. coli using a Luria-
Delbru¨ck fluctuation test [14]. We used the Escherichia coli strain
MG1655 and the concentration of all antimicrobials was adjusted
to limit bacterial growth to 50% in four hours of treatment.
We found that bacteria, when treated with Ampicillin,
Ciprofloxacin and Kanamycin, show 3 to 4 fold increase in
mutation rate consistent with previous reports [15,16]. By
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contrast, none of the groups treated with AMPs or human
Lysozyme, showed changes in comparison to the control
(Figure 1). The differences in mutation rates, as we observed
between antibiotics and AMPs, are sufficient to promote the
evolution of antibiotic resistance [17].
As the killing mechanisms differ between AMP and antibiotics
we repeated the fluctuation assay using a gradient of sub-inhibitory
to inhibitory concentrations of Mellitin and Pexiganan. The
mutation rates did not change (Figure S1). Since the action of
almost all cationic peptide is similar, attraction to the cell
membrane by net charge [12], we assume that this result holds
for many AMPs. It is also possible that the differences in mutation
rates we found are caused by different dynamics in cell death [18]
that may influence the number of cell divisions per culture. This is
a general concern in all experiment estimating the mutation rate
starting from different inoculum sizes [14]. To examine this
possibility we estimated the mutation rate using culture with
different inoculum sizes (102, 104, 106, 108 cfu/ml). In our settings,
all conditions showed similar mutation rates (Figure S2) compa-
rable to that of the control group in our first experiment (Figure 1).
Stress pathway induction by antimicrobial peptides and
antibiotics
SOS and rpoS mediated mutagenesis are well supported by
empirical work [8], and it was recently proposed that antibiotics
promote ROS formation and kill bacterial by lethal induction of
hydroxyl-mediated DNA damage [15]. Here we explored this new
and debated proposition [19] also for AMPs. We assessed AMP
killing curves in E. coli MG1655 in the presence of the ROS
scavenger thiourea (100 mM) and used Kanamycin as positive
control. Consistent with the literature we found reduced sensitivity
to Kanamycin when thiourea is present, the killing effect by
antimicrobial peptides was insensitive to the presence of this ROS
scavenger (Figure S3). AMP killing does not seem to depend on
ROS levels.
To understand more deeply the difference in the bacterial
response to AMPs and classic antibiotics, we used two approaches.
Firstly, we used E. coli reporter strains for the two main stress
pathways, rpoS and SOS in an agar diffusion assay. These two
pathways have been shown to be involved in elevating mutation
rate [8,9]. Yet, AMPs did not activate these pathways (Figure 2) in
contrast to the positive controls. As AMPs are known to attack
mostly the cell membrane, we employed a suite of different stress
pathway genes to assess their expression by qPCR.
We chose 12 stress-pathway genes, comprising components of
the SOS, rpoS and envelope stress pathways (table S3) and
examined their expression under pexiganan, melittin and
lysozyme treatment: only pexiganan elicited an overexpression of
three envelope stress genes (marR, phoP and phoQ) (table S3).
None of the AMP treatments resulted in differential expression of
genes related to stress-induced mutagenesis, which is consistent
with very recently reported results on LL37 [20]. Despite these
consistent results on a lack of stress-pathway induction the study
Figure 1. Changes in mutation rate in E. coli MG1655 induced by different antimicrobial treatments. Error bars show confidence interval
for mutation rate estimation by plating in Rifampicin (100 mg/ml) and using the maximum likelihood method. Each bar represents the mutation rate
from 10 independent cultures. All cultures were treated for 4 hours, with their corresponding MIC50 values for each antimicrobial as follow: 3.2 mg/ml
of ampicillin, 0.05 mg/ml of ciprofloxacine, 1.6 mg/ml of kanamycin, 6 mg/ml of cecropin A, 12.8 mg/ml of human lysozyme, 8 mg/ml of LL-37, 1.6 mg/
ml of melittin, 64 mg/ml of magainin II and 1.6 mg of pexiganan.
doi:10.1371/journal.ppat.1004445.g001
Author Summary
Cationic antimicrobial peptides are ancient and ubiquitous
immune effectors that multicellular organisms use to kill
and police microbes, whilst antibiotics are mostly em-
ployed by microorganisms. Here we provide a new
hypothesis to explain this widespread adoption of antimi-
crobial peptides. We show that cationic antimicrobial
peptides (AMPs) do not increase bacterial mutagenesis, as
they do not elicit bacterial stress pathways. Those stress
pathways increase the mutation rate when bacteria are
treated with antibiotics. Employing AMPs hence seems
advantageous for multicellular organisms, as it does not
fuel the adaptation of bacteria to their immune defenses.
This has important consequences for our understanding of
host-microbe interactions, the evolution of innate immune
defenses, and also sheds new light on antimicrobial
resistance evolution and the use of AMPs as drugs.
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on LL 37 [20] proposes elevated mutagenesis but does not report
mutation rates (see Methods).
Discussion
It is conceivable that the differences in mutation rates we report
are an underestimate of the situation in vivo. In our experiment
we did not study horizontal gene transfer. It is noteworthy that it
has been shown before that alteration of the cell membrane, one of
the primary resistance mechanisms of bacteria against AMPs [4],
reduces cell competence [21]. By contrast, antibiotics eliciting the
SOS response, might not only induce increased mutations via the
DNA repair mechanisms but also lead to enhanced horizontal
transfer [22].
Mutation rate is an important determinant of speed of
adaptation in resistance evolution against AMPs and antibiotics
[15,23],[24]. Theoretical work strongly implies that adaptation to
an antimicrobial in concentration gradients, as presumably
encountered in most natural situations, can be greatly accelerated
by increasing mutation rates through stress-induced mutagenesis
[23]. In this model scenario faster killing, and AMPs tend to kill
quicker than antibiotics [25], further reduces bacterial adaptation
to antimicrobials. While our results are based on E. coli as a model
and a particular panel of AMPs, we suggest, given the conserved
nature of mutagenesis mechanisms in bacteria [8] and the
conserved nature of AMPs in Metazoa [3] it is likely to be a
more general phenomenon.
The fact that AMPs do not elevate mutation rates has, we
propose, at least two more interesting implications. First, symbiont
genome evolution can be accelerated by increased mutation rates
[26] and mutation rate negatively is correlated with genome size in
microbes [27]. Host-symbiont/commensal interactions can be
mediated by AMPs [5][28] but it remains to be seen if and how
the host by employing AMPs does contribute to accelerated
genome reduction in symbionts. Understanding the role of AMPs
in bacterial mutagenesis will, we suggest, help to understand
animals in a bacterial world [29]. One other interesting aspect is
that the generation times of metazoans and their commensal,
symbiotic or pathogenic bacteria often differ by orders of
magnitude [30] resulting in within-host evolution of bacteria.
The benefit of AMPs for the metazoan host can be considered to
not further fuel the evolvability of the bacteria. By contrast,
antimicrobials produced by bacteria are used in the context of
interactions between organisms with very similar generation times.
Secondly, AMPs are used as antimicrobial drugs. In vitro
experiments showed that adaptation to AMPs displays similar
kinetics as antibiotic resistance evolution [31]. The situation in
vivo, when a drug is used to support the overwhelmed immune
system is almost certainly very different. The additional benefit of
an unaltered mutation rate (including reduction in HGT) under
AMP treatment contrasts with elevated mutation rates under
antibiotic treatment. Changes in the mutation rate as reported
here are in the range of mutation rates closely linked with disease
emergence [32] and evolutionary rescue of populations of
microorganisms [33].
Materials and Methods
Bacterial strains and growth conditions
E. coli K-12 MG1655 was used for all experiments, grown in
liquid Mueller-Hilton (MH) agar or agarose, unless otherwise
indicated. All experiments were carried out at 37uC.
Preparation of reporters
The plasmid pUA66-PrecA::GFP harbors a green fluorescent
protein (GFP) transcriptional fusion with the recA promoter that is
under control of lexA [34]. The plasmid was introduced into the
electrocompetent cells of the strain MG1655 by electroporation.
Transformed clones were selected on LB agar plates containing
30 mg/ml of kanamycin. The expression of GFP under SOS
activation was determined by observing the fluorescence close to
the inhibition area after addition of the SOS inducer mitomycin
C.
A chromosome-integrated fusion reporter for rpoS with b-
galactosidase, kindly provided by Regine Hengge (Humboldt
University of Berlin, Germany), was transferred from the strain E.
coli MC4100 via P1vir phage transduction to the E. coli strain
MG1655 DlacZ. The reporter contains the hybrid protein
RpoS742::LacZ (which carries the N-terminal 247 amino acids
Figure 2. Antimicrobial peptides do not elicit the SOS (top panel) or the rpoS pathway (bottom panel). Induction of the SOSresponse or
rpoS response is shown by a fluorescent ring around the zone of clearance (green for recA::GFP, blue for rpoS::b-gal at the edge of the inhibition
zone). Positive controls with antibiotics (Cip: Ciprofloxacin, Ap: Ampicillin) are shown on the left. The bright central disc is a filter paper as source of
the antibiotic/antimicrobial [22]. The amount of animicrobials on paper disks consisted of 50 mg of ampicillin, 5 mg of ciprofloxacine, 50 mg of
cecropin A (Cec-A), 256 mg of human lysozyme (h-Lys), 50 mg of LL-37, 20 mg of Melittin, 200 mg of magainin II, and 20 mg of pexiganan.
doi:10.1371/journal.ppat.1004445.g002
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which include a2.5 of sS). This reporter preserves post-
translational proteolytic control of sS expression [35].
The strain MG1655 DlacZ was obtained by disrupting the
entire lacZ gene. Briefly, transformants carrying a red recombi-
nase helper plasmid, pKD46, were grown in 5-ml SOB medium
with ampicillin (100 mg/ml) and L-arabinose at 30uC to an
OD600 of <0.6 and then made electrocompetent. PCR products
with homology regions were gel-purified, digested with restriction
enzyme DpnI, column purified (MinElute PCR Purification Kit,
Qiagen). Competent cells in 50 ml aliquots were electroporated
with 100 ng of PCR product. Cells were added immediately
0.9 ml of SOC, incubated 1 h at 37uC, and then 100 ml aliquots
spread onto LB agar with kanamycin (30 mg/ml), 40 ug/ml of 5-
bromo-4-chloro-3-indolyl-3-D-galactoside (X-Gal) and 0.1 mM of
isopropyl b-D-thiogalactopyranoside (IPTG). White colony resis-
tant transformants were selected after 24 h of incubation. The
correct inactivation of lacZ gene was verified by PCR.
The RpoS742::LacZ reporter construct was transferred from
MC4100 to the strain E. coli MG1655 DlacZ following an
improved protocol describe by Moore for P1 vir phage
transduction with minor modifications. The transduced strain
was selected on agar plates with M9 minimal medium containing
1% of lactose as only carbon source and supplemented with
kanamycin (20 mg/ml) and 40 ug/ml of X-gal. A few blue
transformants were regrown in MH with kanamycin (30 mg/ml).
The phenotype of the new strain, namely MG1655 rpoS::lacZ, was
verified by monitoring the b-galactosidase activity as described by
Miller [33]. A correct phenotype corresponded with a growing b-
galactosidase expression from exponential phase to stationary
phase as sS does. Briefly, overnight cultures of MG1655 DlacZ
(negative control) and its derivative containing the fusion reporter
RpoS742::LacZ were diluted 1:100 in 100 ml of LB. After 2 hours
(OD600,0.5), the pellets of six sequential aliquots of 1 ml, that
were taken at intervals of 1 hour (from the mid exponential phase
to stationary phase) were re-suspended in 1 ml of Z-buffer
(NA2HPO4 16.1 g/L, NaH2PO4 5.5 g/L, KCl 0.75 g/L, MgSO4
0.246 g/L and b-mercaptoethanol 0.3% (v/v). Bacteria were lysed
with 0.1% SDS and 20 ml of chloroform. The reaction was started
by adding 200 ml of ONPG (4 g/ml) per tube, and it was stopped
by the addition of 500 ml of 1 M NaCO3 solution (pH 9). The
experiment was done at room temperature. b-galactosidase
activity was expressed as Miller units.
Soft-agarose transcription fusion reporter assay for rpoS
and recA reporter assay
All antibiotics were purchased from Carl Roth GmbH,
pexiganan was kindly provided by M. Zasloff (Georgetown
University), melittin was purchased from Serva, and human
lysozyme was obtained from Sigma. To qualitatively assess
antimicrobial-mediated induction of both stress pathways, over-
night cultures of the recA (SOS pathway) and and rpoS (general
stress response sS) reporters, were diluted 1 in 100 in fresh MH
and cultivated with shaking to mid exponential phase
(OD600,0.5). Aliquots of 2.5 ml of culture were mixed in equal
part with MH containing 0.6% of pre-cooled agarose (to a final
concentration of 0.3% of agarose) at 40uC and were poured
immediately onto MH agarose plate at 1.5%. In the case of
MG1655 rpoS::lacZ strain, the plates also contained X-gal to a
final concentration of 40 mg/ml, and 80 mg/ml for the pre-cooled
agarose. Antimicrobial-containing filter discs of Watman No. 1
(5 mm Ø) were deposited onto the middle of agarose plates and
were incubated during 6 and 24 hours before visualization at
37uC. Discs with ciprofloxacin (5 mg) and ampicillin (10 mg) were
used as positive control to assess the induction of recA and rpoS
respectively. The others disks contained different concentrations of
antimicrobial peptides to obtain a similar inhibition area: 50 mg of
cecropin A (Cec-A), 256 mg of human lysozyme (h-Lys), 50 mg of
LL-37, 20 mg of Melittin, 200 mg of magainin II, and 20 mg of
pexiganan. The plates carrying recA reporter were observed using
a blue light transiluminator (Biosteps GmbH, Germany) for
excitation of the GFP and a filter (502–538 nm) to visualize the
emission of fluorescence, while the plates with MG1655 rpoS::lacZ
reporter were observed under natural light for direct visualization
of a blue ring of X-gal hydrolysis surrounding inhibition area, in
case of induction. All assays were repeated at least three times.
Minimal inhibitory concentration (MIC)
MICs were determined according to CLSI recommendations by
a micro-dilution method with the exception that the inoculum size
that was adjusted to 26108 cfu/ml from a regrowth of overnight
cultures to be consistent with the mutagenesis experiments. The
MIC was defined as the antimicrobial concentration that inhibited
growth after 24 h of incubation in liquid MH medium at 37uC.
Polypropylene non-binding plates (Th. Geyer, Germany) were
used for all experiments.
Determination of MIC50
The MIC50s for all antimicrobials were determined by
inoculating strains grown to mid-log phase into the wells of a
96-microwell plate. Approximately 102 cells from overnight
cultures were inoculated into tubes containing 10 ml of Mueller
Hinton Broth medium, and the tubes were incubated at 37uC with
strong shaking until the mid-log phase of growth (approximately
108 cells/ml). Then, 100 ml of 2–36108 cells from these cultures
were inoculated into each well containing 100 ml of Mueller
Hinton Broth and starting from the MIC concentrations were
serially diluted by a factor of 2 (lowest concentration 1/128 of the
MIC) for all antimcirobials. The plates were incubated at 37uC for
4 h with continuous shaking in a plate reader (Synergy 2,
BioTeK). After four hours, aliquots from wells with OD600
readings ranging from 10 to 90% values in comparison with the
control, were serially diluted in sterile 0.9% NaCl, and incubated
during 1 hour to allow the resolution of filaments as consequence
of SOS activation, if any. Bacterial suspensions were plated in
Mueller Hinton Broth agar plates to estimate the viability as
colony forming units (CFUs). Five replicates per concentration
were prepared and the experiments were repeated twice. MIC50s
at 4 hours were defined as the concentrations at which 50% of
growing reduction in terms of CFUs in comparison to the control
were observed.
Mutagenesis experiments
To understand mutagenesis the most important parameter to
estimate is the mutation rate using a fluctuation assay [14], other
possible correlates of mutagenesis have severe shortcomings (for
example mutant frequencies as reported in a recent study on LL37
[20], a detailed description of the methodological problems is
available on request).
In order to obtain comparable results from the activity of classic
antibiotics and AMPs, the mutation rate experiments were
performed as follows. The duration of treatment was set to
4 hours for all antimicrobials, and the concentrations were
adjusted to obtain around 50% of inhibition of grow in
comparison to the a non-treated control. Three ml of exponen-
tially growing culture of E. coli MG1655 (,26108 cells/ml) were
centrifuged at 4000 g for 10 minutes and re-suspended in the
same volume of MH with different concentrations of antimicro-
bials at 37uC with shaking (200 rpm). After incubation, the
Antimicrobials, Stress and Mutagenesis
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cultures were centrifuged for 10 min at 4000 g. The pellet was re-
suspended, washed twice with MH and re-suspended in 3 ml of
fresh medium and incubated overnight (16 h) at 37uC with
shaking. This step is necessary to resolve the filaments that some
antimicrobials induce due to their toxic action and allow recovery
of cells under stress. Cultures were diluted and plated to determine
the number of colony forming units in MH agar plates. The
number of mutants was estimated by the number of colonies
growing on rifampicin (100 mg/ml). Mutation rates were calculat-
ed by maximum verisimilitude method and data were processed
using the on-line web-tool for mutation rate determination Falcor
(http://www.mitochondria.org/protocols/FALCOR.html). Every
experiment consisted of ten independent cultures. The whole
experiment was repeated twice.
We also assessed if different AMP concentrations (Fig. S1) or
different inoculum sizes (102, 104, 106, 108 cfu/ml) influenced
mutation rates (Fig. S2).
Killing by AMPs under thiourea ROS scavenger
For two antimicrobial peptides, melittin and pexiganan, we
assayed their respective MIC values in the presence or absence of
the protective concentration of 100 mM of thiourea. Kanamycin
was used a positive control. The procedure was the same as
described in this work elsewhere for MIC50 (Fig. S3).
Quantification of gene expression, sample acquisition
Escherichia coli strain MG1655 was used to assess the response
of twelve stress pathways-related genes to three antibiotics
(kanamycin, ciprofloxacin and ampicillin) and two antimicrobial
peptides (AMPs) (pexiganan, melittin) and human lysozyme in
comparison with a non-treated control. Preparation of each of the
six treatments and the control samples was carried out by two
operators on three consecutive days, thereby comprising three
biological replicates for each of the six experimental and one
control groups. To obtain the starting material for the experiment,
a fresh bacterial culture was grown from a glycerol stock on
Mueller-Hinton (MH) agar plates at 37uC for 18–24 hours. One
well-isolated colony per biological replicate was used to inoculate
2 ml of liquid MH (Sigma) in a 10 ml sterile polypropylene tube
and incubated at 37uC for 16 hours with mild shaking. The
overnight (ON) culture was then diluted 1:100 in MH, subdivided
into seven 10 ml aliquots and incubated in 50 ml-Falcon tubes at
37uC for 2.5 hours at 220 rpm. When the OD600 of bacterial
cultures reached 0.5–0.7, respective antibiotics and AMPs were
added to a concentration to match with those used in the
mutagenesis experiments. These bacterial cultures were incubated
for 20 minutes at 37uC with gentle shaking. Two ml of bacterial
cultures from each treatment and the control were collected,
immediately centrifuged at 10000 g for 2 minutes and the
supernatant was removed to stop the treatment. The bacterial
pellet was then resuspended in 1 ml MH, followed by an addition
of 1 ml of RNAprotect Bacteria Reagent (Qiagen), 5 minutes
incubation and centrifugation at 10000 g for 2 minutes at room
temperature. The supernatant was discarded and the bacterial
pellet was immediately frozen and stored at 280uC until RNA
extraction.
Quantification of gene expression, RNA isolation
Total RNA was isolated using RNeasy kit (Qiagen) according to
the manufacturer’s instructions and eluted in 50 ml of RNase-free
water. The nucleic acid yield and purity were determined by
measuring the optical density at A260/280 using a Nanodrop
spectrophotometer (Thermo Scientific). RNA samples were
treated with TURBO DNase (Life Technologies). Briefly, ten mg
of RNA were used in a total volume of 500 ml containing 20 units
of TURBO DNase, incubated for 30 minutes at 37uC, immedi-
ately followed by RNeasy (Qiagen) cleanup and elution in 30 ml of
RNase-free water. Following DNase treatment, RNA integrity was
assessed using Agilent RNA 6000 Nano kit and 2100 Bioanalyzer
instrument (both Agilent Technologies). All samples had RIN
values above 8.
Quantification of gene expression, cDNA synthesis
High-Capacity cDNA Reverse Transcription Kit with RNase
Inhibitor (Applied Biosystems) was used for cDNA synthesis.
Initially, to ensure linear conversion of the transcripts, the dynamic
range of reverse transcription reaction was tested by performing a
standard curve with cDNA, synthesised using various input
amounts of pooled RNA. Total RNA (250 ng per reaction) and
random primers were used for cDNA synthesis. To obtain
sufficient amount of cDNA, several batches of 20 ml RT reactions
were pooled, diluted 50-fold with RNase-free water and stored in
single-use aliquots at 280uC until further use. All 21 samples were
tested for presence of contaminating genomic DNA by running the
mdoG assay with cDNA and the respective no reverse transcription
(2RT) controls. There was no amplification in the majority of 2
RT controls. In 2RT samples with detectable amplification,
difference in Ct values when compared with +RT varied between
the samples, but was no less than 10 cycles for all of them with the
lowest Ct values in 2RT control samples $30.
Primer design
Escherichia coli strain K-12 substrain MG1655 complete
genome (accession U00096) sequence was downloaded from
NCBI database (www.ncbi.nlm.nih.gov) and used for primer
design. Target sequence accession number, location of the
amplicon, amplicon length and primer sequences for each assay
can be found in table S2. Primers were designed using Primer
Express software (Applied Biosystems) and optimized for annealing
temperature of 60uC. Each primer pair and amplicon were
checked for secondary structure formation using Oligo Tool
(Integrated DNA technologies, http://eu.idtdna.com/analyzer/
Applications/OligoAnalyzer/). Primer and amplicon specificities
were first tested in silico by performing a BLAST search against
the complete genome. Primers were synthesised by Metabion
GmbH (Germany) and purified by desalting.
Quantification of gene expression, quantitative real-time
PCR
PCR reactions were prepared manually in a total volume of
10 ml by mixing 5 ml 26KAPA SYBR FAST ABI Prism master
mix (KAPA Biosystems), 0.2 ml forward and reverse primer mix
(10 mM each primer), 2.8 ml RNase-free water and 2 ml cDNA in
MicroAmp Fast Optical 48-wells reaction plates (Applied Biosys-
tems). PCR reactions were run in the Fast mode using StepOne
thermocycler (Applied Biosystems) with the following cycling
conditions: 95uC 39/406(95uC 30/60uC 200)/melting curve
analysis. Each assay was run in duplicate. No template controls
(NTC) were run with each assay. Presence of a single specific
product was verified by running a melt curve analysis followed by
visualisation of the qPCR product in a 2% agarose gel stained with
SYBR Safe DNA Gel stain (Life Technologies). qPCR amplicons
of each gene were cloned into the pGEM-T vector (Promega)
following the instructions manual and subsequently sequenced to
confirm the specificity of the assays. Additionally, each PCR assay
was tested for reaction efficiency as follows: equi-molar amounts of
cDNA from all 21 samples were pooled together and used for the
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preparation of the standard curve by serial dilution (1:3) of pooled
cDNA over five dilution points and run in triplicate.
Quantification of gene expression, data analysis
Amplification curves were first visually examined in the
StepOne software (Applied Biosystems). No baseline and threshold
line adjustments were necessary. Ct values of the technical
replicates were averaged and used for relative gene expression
analysis in the REST 2009 software (Qiagen). Expression of target
genes was normalized to the expression levels of three reference
genes (arcA, mdoG and tus), selected based on the assessment of
the expression stability across all experimental conditions using
BestKeeper software [36]. Reaction efficiency information inferred
from the standard curve data was used to correct for differences in
amplification efficiencies in the REST 2009 software. Default
settings (2000 iterations) were used for randomisation and
bootstrapping analysis to test significance of gene expression.
Expression values with p-values #0.05 were assigned as differen-
tially expressed. The relative gene expression results can be found
in the supplementary Table.
Quantification of gene expression, MIQE standards
The Minimum Information for Publication of Quantitative
Real-Time PCR experiments (MIQE) guidelines-compliant check-
list were fulfilled.
Supporting Information
Figure S1 Mutation rates of E. coli MG1655 from
cultures with different concentrations of antimicrobial
peptides. The cultures were treated with melittin and pexiganan
with concentrations ranging from 0.5 to 4 mg/ml. Note that higher
concentrations cannot be assayed because they are lethal and as
AMPs kill much quicker than antibiotics the cultures do not
recovered from the treatment. Error bars show confidence interval
for mutation rate estimation by plating in Rifampicin (100 mg/ml)
and using the maximum likelihood method.
(PDF)
Figure S2 Mutation rates of E. coli MG1655 from
cultures with different inoculum sizes. Error bars represent
95% of confidence intervals. Error bars show confidence interval
for mutation rate estimation by plating in Rifampicin (100 mg/ml)
and using the maximum likelihood method.
(PDF)
Figure S3 Killing curves of AMPs and kanamycin in the
presence of 100 mM of thiourea.
(PDF)
Table S1 MIC and MIC50 (4 hours) values for E. coli
MG1655 for different antibiotics and antimicrobial
peptides.
(PDF)
Table S2 Primers used for relative gene expression
quantification by real time PCR.
(PDF)
Table S3 Relative gene expression for E. coli stress
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